Pharmasyntez is one of leading biopharmaceutical companies in Russia and operates across various segments of the healthcare industry. This includes research, development, production, and distribution of medicines for treatment of socially significant diseases, innovative medicines, and active pharmaceutical ingredients.
The production facilities of the Pharmasyntez Group are represented by five high-tech plants across Russia: in Ussuriysk, Irkutsk, Bratsk, Tyumen, and St. Petersburg. The annual production output of the Pharmasyntez Group exceeds 100 million packages. The company employs over 5,000 people.
Pharmasyntez develops and manufactures modern medicines for a wide range of medical applications, including oncology, hematology, endocrinology, immunology and cardiology, as well as medicines for treatment of orphan, hormonal, infectious, autoimmune and cardiovascular diseases. The company's portfolio includes medicines for treatment of diabetes, tuberculosis, hepatitis, HIV infection, COVID-19, chronic renal failure, as well as products for maintaining patients with severe conditions, for example, solutions for parenteral nutrition, etc.
R&D center for biotechnological medicines of Pharmasyntez Group is one of the largest in Russia. Its ongoing research and development projects are aimed at creating a new generation of innovative treatment methods in oncohematology, gynecology, virology and endocrinology.
The company's product portfolio includes more than 300 names of medicines and over 80 names of pharmaceutical ingredients. More than 80% of the company’s products are included in the list of life-saving medicines.
Pharmasyntez is one of the largest investors in the Russian pharmaceutical industry. To date, over 23 billion rubles (280 million USD) have been invested in extension of production capacities and new reserch and development activities. Consolidated revenue for 2024 is amounted to 50.1 billion rubles (640 million USD).